A paradigmatic example, is provided by the Losartan Intervention For Endpoint reduction in hypertension trial in which the presence of left ventricular hypertrophy (LVH) or microalbuminuria (MAU) or both at baseline was associated with a significant increased risk of developing the primary composite endpoint (myocardial infarction, stroke and cardiovascular mortality) and mostly stroke during the